Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.67 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.49 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.49 |
| ▸ | ASPH | Q12797 | 1/20 | 0.49 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247183 | 0.96 | HIF1A (0.62) | HIF1AEGLN3EGLN1EGLN2BBOX1 | |
| SCHEMBL8245604 | 0.95 | HIF1A (0.61) | HIF1AEGLN3EGLN1EGLN2BBOX1 | |
| SCHEMBL5308270 | 0.85 | HIF1A (0.74) | HIF1AEGLN1BBOX1ASPHKDM8 | |
| SCHEMBL8249796 | 0.85 | HIF1A (0.58) | HIF1AEGLN3EGLN1EGLN2 | |
| SCHEMBL8245606 | 0.83 | HIF1A (0.56) | HIF1AEGLN3EGLN1EGLN2 | |
| SCHEMBL8248071 | 0.83 | HIF1A (0.56) | HIF1AEGLN3EGLN1 | |
| SCHEMBL8237955 | 0.83 | EGLN1 (0.64) | HIF1AEGLN3EGLN1 | |
| SCHEMBL8248316 | 0.82 | HIF1A (0.55) | HIF1AEGLN3EGLN1EGLN2 | |
| SCHEMBL8244124 | 0.81 | EGLN1 (0.59) | HIF1AEGLN3EGLN1 | |
| SCHEMBL8237984 | 0.81 | HIF1A (0.68) | HIF1AEGLN1BBOX1ASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118141933-A | Use of EGLN3 inhibitors for the preparation of a medicament for the treatment of AML | 细胞生态海河实验室 | 2024-06-07 | — | — | CN | claimed |
| WO-2023107977-A1 | METHODS AND COMPOSITIONS FOR TREATING AIRWAY INFLAMMATION | THE UNIVERSITY OF CHICAGO (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4423242-A1 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118141933-B | Use of EGLN3 inhibitors for the preparation of a medicament for the treatment of AML | 细胞生态海河实验室 | 2024-08-13 | — | — | CN | disclosed |
| CN-118141933-A | Use of EGLN3 inhibitors for the preparation of a medicament for the treatment of AML | 细胞生态海河实验室 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024090329-A1 | COMPOSITION FOR AMELIORATING INFLAMMATION ASSOCIATED WITH CHRONIC HYPOXIA | 国立大学法人東北大学 | 2024-05-02 | — | — | WO | disclosed |
| CN-117836404-A | Method for producing kidney interstitial precursor cells, erythropoietin-producing cells, and method for producing renin-producing cells | 国立大学法人京都大学 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023076292-A9 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023107977-A1 | METHODS AND COMPOSITIONS FOR TREATING AIRWAY INFLAMMATION | THE UNIVERSITY OF CHICAGO (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023076292-A1 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023017848-A1 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | 国立大学法人京都大学 | 2023-02-16 | — | — | WO | disclosed |
| WO-2007038571-A2 | PROLYL HYDROXYLASE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |